Calendar

REGISTER | SCHEDULE | PROGRAM BOOK | SPEAKERS | POSTER INFO | SPONSORS

Join us for the IRM’s spring symposium! This year, we are taking a comprehensive look at hematopoietic stem cells: their biology, their failure in bone marrow syndromes, and their use in gene therapy approaches. Come learn all about these topics and more from Penn experts and leaders from around the world. Consistent with COVID-19 related health guidelines, this will be a virtual event.

Keynote

Sean Morrison, Ph.D. UT Southwestern

Speakers

Jeff Magee, M.D., Ph.D. Washington University St. Louis

Daniel Lucas, Ph.D. Cincinnati Children’s Hospital

Camilla Forsberg, Ph.D. UC Santa Cruz

Paula Rio Galdo, Ph.D. CIEMAT/CIBERER, Spain

Saar Gill, M.D., Ph.D. University of Pennsylvania

Stefano Rivella, Ph.D. Children’s Hospital of Philadelphia

Vijay G. Sankaran, M.D., Ph.D. Boston Children’s Hospital

Akiko Shimamura, M.D., Ph.D. Dana-Farber Cancer Institute

Daria Babushok, M.D., Ph.D. University of Pennsylvania

Lightning Talks and Posters

We are excited to offer students and postdoctoral researchers the opportunity to present during this event! Trainees working in the broad area of hematopoietic stem cell biology or related disease and therapy areas are invited to submit abstracts for posters and consideration for lightning talks! Please read the information below and indicate your preferences during registration. Prizes will be awarded!

Lightning talks: A select number of trainees will be chosen to present 1 slide, 90-second overviews of their research during the main session of our event.  These talks are “pitches” or previews of your poster sessions and should get your colleagues excited to come learn more about your work. Lightning talk speakers will be chosen from submitted abstracts and notified the week prior to our event.

Posters: Posters will be presented during our lunch hour in individual Zoom rooms. Please create a short slide deck corresponding to the sections of a traditional poster (Introduction, Methods, Results, Conclusions, etc.). Attendees will be free to circulate into your Zoom room and listen as you present and ask questions. Judges will evaluate posters for potential prizes!

Abstract format and submission

Abstracts must include a title, authors and affiliations, and no more than 250 words describing the research.

Abstracts are due by 5 PM EST on Friday, February 26th. Submit abstracts via email to yaroshc@pennmedicine.upenn.edu. Use “HSC Symposium Abstract” as the subject line.

Sponsors

Thank you to our generous sponsors:

	Founded by scientists, Proteintech Group recognises the tireless efforts and sacrifices made by researchers to advance scientific discovery. Proteintech aims to match its’ customers’ dedication to research with high quality, reliable reagents that contribute to reproducible results. Learn about their human cell-expressed, recombinant proteins.
	The future of advanced medicines relies upon deeper access to in vivo biology to create durable, curative impacts on disease. IsoPlexis’ systems, which drive convergence of dynamic proteomics and single cell biology for the first time, are creating this deeper connection to accelerate curative medicines.
	The Pediatric Comprehensive Bone Marrow Failure Center (CBMFC) at Children’s Hospital of Philadelphia (CHOP) was established in 2010 as a comprehensive, multidisciplinary center dedicated to providing world-class care for children and adults with inherited and acquired forms of bone marrow failure (BMF). The CBMFC at CHOP collaborates with partners at the University of Pennsylvania (Penn) for both clinical and research efforts.
	Penn’s Hematology/Oncology Division is a comprehensive program dedicated to the clinical care and research, providing the most advanced treatment for all types of cancers and blood-related disorders. Our faculty members, more than 130, are involved in research to develop new and more effective methods for diagnosing and treating these diseases and for educating the physicians and researchers of the future.
	The Sickle Cell and Red Cell Disorders Curative Therapy Center (CuRED) offers integrated and coordinated care from multiple pediatric specialists for children with sickle cell disease, thalassemia, and other red cell disorders. The CuRED team provides patients with a comprehensive evaluation and individualized cutting-edge treatments for management of their chronic disease, while exploring the potential for a curative therapy. CuRED is also driving towards the development of their own gene therapy for sickle cell disease and thalassemia leveraging CHOP’s world-class translational research expertise. The program’s mission is to continue to advance the field of curative therapies across a full range of red blood cell disorders.
	The Division of Hematology at Children’s Hospital of Philadelphia provides inpatient and outpatient services for children and adolescents with all hematologic disorders other than malignancies.
	Research in the Division of Oncology falls under Children’s Hospital of Philadelphia Center for Childhood Cancer Research, which was established more than a decade ago as a state-of-the art program that integrates a wide array of basic, translational, and clinical research efforts. The Center brings together the diverse talents of investigators in Children’s Hospital renowned multidisciplinary program in pediatric cancer research, patient care, and genomics.
	The Hematologic Malignancies Program at the Abramson Cancer Center drives basic scientific discoveries and translates them into novel therapeutics for patients with myeloid and lymphoid neoplasms. Formed in 1994, the Program has two scientific aims: 1) Develop a mechanisms-based understanding of the genetic, cellular, and biochemical processes regulating malignant hematopoiesis; and 2) Translate basic scientific discoveries into more effective and less toxic therapies for hematologic malignancies.
	As the premier scientific marketplace, Fisher Scientific has defined unparalleled choice and convenience for over a century. Focused first and foremost on delivering innovative yet eminently practical solutions, we have developed a comprehensive portfolio of laboratory equipment and supplies, chemicals, safety products, and services to help our customers increase productivity and drive innovation in research, healthcare, education and industry — all with greater ease and efficiency than ever before.